France Bladder Cancer Market Projected to Reach $395.8 Million by 2035

France bladder cancer market was valued at $243.6 million in 2025 and is projected to reach $395.8 million by 2035, growing at a CAGR of 5.0% during the forecast period (2026–2035). In the France bladder cancer market, innovations in diagnostic technologies are playing an increasingly important role in improving clinical management and long-term surveillance. While therapeutic advancements remain central, non-invasive diagnostic tools are reshaping early detection and recurrence monitoring strategies, particularly for non-muscle invasive bladder cancer (NMIBC). Traditional follow-up relies heavily on cystoscopy, an invasive and resource-intensive procedure, creating a demand for complementary diagnostic approaches. Recent clinical collaborations and registry-based evaluations in France are further strengthening the evidence base for non-invasive bladder cancer diagnostics. For instance, in October 2023, Nucleix announced that its Bladder EpiCheck test will be included in the registry of the Association Francaise d'Urologie (AFU) for the surveillance of non-muscle-invasive bladder cancer (NMIBC) in France. The TVNIM-AFU registry will evaluate the diagnostic performance of selected urinary biomarkers over a two-year follow-up period and compare results with routine cystoscopy findings in patients undergoing monitoring after tumor resection. Bladder EpiCheck is a CE-marked urine test in Europe and has received US FDA 510(k) clearance for detecting bladder cancer recurrence; prior EU studies reported 91% sensitivity and 99% negative predictive value for high-grade recurrent disease. By enabling non-invasive sample collection and laboratory-based analysis, such technologies may help optimize surveillance intervals and reduce procedural burden in selected patient populations. These advancements align with broader trends toward precision medicine and evidence-based follow-up protocols. As healthcare systems increasingly focus on cost efficiency and patient quality of life, molecular diagnostic innovations are expected to contribute meaningfully to the evolution of bladder cancer care in France.

Browse the full report description of “France Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other Rare Types) By Diagnosis Method (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (Ivp), and Other) By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other), 2026–2035” at https://www.omrglobal.com/industry-reports/france-bladder-cancer-market

Incidence of Bladder Cancer in France

• In 2023, an estimated 14,062 new cases of bladder cancer were recorded in France, making it one of the more common cancers nationally. About 81% of these cases occurred in men, reflecting the disease’s strong male predominance.

• Bladder cancer ranks approximately 5th among all cancers in France by incidence.

• The age-standardised incidence rate is estimated at around 14–15 per 100,000 men and approximately 2–3 per 100,000 women, highlighting a significant gender disparity.

Competitive Landscape and Emerging Clinical Innovations in the France Bladder Cancer Market

The France bladder cancer market is characterized by the presence of several leading global pharmaceutical companies, including Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Merck & Co., Inc., and Roche Holding AG, among others. These organizations play a significant role in shaping the competitive landscape through their established oncology portfolios, ongoing clinical development programs, and strategic collaborations within the region.

• Atonco and the Institut de Cancérologie de l’Ouest (ICO) have received authorization to initiate the Phase I PERSEVERANCE EU clinical trial (NCT07260162), the first study in France to evaluate astatine-211 in patients with non-muscle-invasive bladder cancer refractory to standard treatment. The study follows prior feasibility data from the PERTINENCE trial (NCT04897763) and represents an early-stage evaluation of targeted alpha therapy in urothelial oncology, with patient enrollment planned at the ICO site in Saint-Herblain.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Cancer Type
  • Diagnosis Method
  • Therapy
• Competitive Landscape - Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Merck & Co., Inc. and Roche Holding AG, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

France Bladder Cancer Market Report Segment

Cancer Type 

• Transitional Cell Bladder Cancer/Urothelial Carcinoma
• Squamous Cell Bladder Cancer
• Adenocarcinoma
• Others

Diagnosis Method

• Cystoscopy
• Biopsy
• Urinalysis
• Urine Cytology
• Intravenous Pyelogram (IVP)
• Others

By Therapy

• Surgery
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Others

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/france-bladder-cancer-market